Mini Review : Liver Fibrosis Mechanism
Abstract
Liver fibrosis is the process of wound healing in the liver that caused by a various causes. The longer time of wound healing process, the more severe disorder will be. This chronic condition is characterized by excessive deposition of extracellular matrix then ended with fribrosis. This mini review describes about the phase of liver fibrogenesis. Even though there are many variations of fibrogenesis in animals and human, in general there are three fibrogenic cells that involved in fibrogenesis. These three cells are fibroblast or endogenous fibroblast like-cells, epithelial to mesenchymal transition (EMT), and fibrocytes that derived from bone-marrow.
Keywords : liver, fibrosis, fibroblast, EMT, fibrocytes, collagen
References
[1] Kisseleva T and Brenner D A, 2008. Fibrogenesis mechanism. Exp Biol Med, 233(2): 109-122.
[2] Guiterrez-Ruiz C, Robles-Diaz G, Kershenobich D, 2002. Emerging concepts in inflammation and fibrosis. Archieves of medical research 33: 595-599.
[3] Steen, V. 2006. Targeted therapy for systemic sclerosis. Autoimmun Rev 5: 122– 124.
[4] Lee, U.E., and Friedman, S.L. 2011. Mechanisms of Hepatic Fibrogenesis. Best Pract Res Clin Gastroenterol, 25(2): 195– 206.
[5] Suematsu M, Suzuki H, Delano FA, Schmid-Schonbein GW. 2002. The inflammatory
aspect of the microcirculation in
hypertension: oxidative stress, leukocytes/endothelial interaction, apoptosis. Microcirculation, 9:259–276.
[6] Kumar V, Abbas AK and Pausto N, 2005. Tissue renewal and repair: regeneration, healing and fibrosis. Elsevier Saunders, Philadelphia, pp 87-118.
[7] Wynn, TA., 2007. Common and unique
mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest, 117:524–529.
[8] Lama VN and Phan SH, 2006. The extrapulmonary origin of fibroblasts : stem/progenitor cells and beyond. Proc Am Thorac Soc, 3;373-376.
[9] Kolaczkowska, E and Kubes P. 2013. Neutrphil recruitment and function in health
and inflammation. Nature Review Immunology, 13(3):159-169.
[10] Kang DH, and Johnson RJ. 2003. Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens, 12:43–49.
[11] Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI. 2007. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis.
[12] Ushio-Fukai M., 2007 VEGF signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal, 9:731–739.
[13] Kuwano K, Hagimoto N, Nakanishi Y, 2004. The role of apoptosis in pulmonary fibrosis. Histopathol, 19:867-881.
[14] Yamaji-Kegan, K., Su, Q., Angelini, D.J., Myers, A.C., Cheadle, C and Johns, R. A. 2010. Hypoxia-Induced Mitigenic Factor
(HIMF/FIZZ1/RELMα) Increases Lung
Inflammation and Activated Pulmonary Microvascular Endothelial Cells via an IL-4-
Dependent Mechanism. J Immunol, 185:5539-5548.
[15] Sheppard D, 2006. Transforming growth factor 4 beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc, 3:413-417.
[16] Hayashi, H., and Sakai, t. 2012 Biological significance of local TGF-β activation in liver diseases. Front Physiol, 3(12):1-12.
[17] Leask A and Abraham DJ, 2004. TGF-beta signaling and the fibrotic response. FASEB J, 18:816-827.
[18] Breitkopf K, Godoy P, Ciuclan L, Singer MV, Dooley S, 2006. TGF-beta/Smad signaling in the injured liver. J Gastroenterol, 44:57-66.
[19] Ten Dijke F and Hill CS, 2004. New insight into TGF-beta-Smad signaling. Trends Biochem Sci, 29:265-273.
[20] Wells, R.G. 2000. Fibrogenesis. V. TGF-beta signaling pathways. Am J Physiol Gastrointest Liver Physiol, 279(5):G845-G850.
[21] Dooley, s., and ten Dijke P. 2012. TGF-
β in progression of liver disease. Cell Tissue Res, 347: 245-256.
[22] Dooley S, Delvoux B, Streckert M, Bonzel L, Stopa M, ten Dijke P. Gressner AM, 2001. Transforming growth factor beta
signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbeta signal transduction during transdifferentiation of hepatic stellate cells. FEBS Lect, 502:4 –10.
[23] Cong, M., Iwaisako, K., Jiang, C., and Kisseleva, T. 2012. Cell signals Influencing Hepatic fibrosis. Int J of Hepatology, 1-18.
[24] Duval. F., Moreno-Cuevas, J.E., Gonzalez-Garza, M. T., Maldonado-Bernal, C, and Cruz-vega D. E. 2015. Liver Fibrosis and Mechanism of the Protective Action of Medicinal Plant Targeting Inflammation and The immune Response. Int J of Inflam, 1-14.
[25] Bataller R and Brenner DA, 2005. Liver fibrosis. J Clin Invest, 115(2): 209-218.
[26] Xu, R., Zhang, Z., and Wang, S. 2012. Liver fibrosis: mechanisms of immune-mediated liver injury. Cell Mol Immunol, 9(4): 296–301
[27] Parola M and Pinzani M, 2009. Hepatic wound repair. Fibrogenesis and Tissue repair, 2(4): 1-6.
[28] Mormone, E., George, J., and Nieto, N. 2011. Molecular Pathogenesis of Hepatic
Fibrosis and Current Therapeutic approaches. Chemoco-Biological Interaction, 193: 225-231.
[29] Li, S., Tan, H., Wang, N., Zhang, Z. J., lao, L., Wong, C. W., and Feng, Y. the Role of Oxidative stress and Antioxidants in Liver diseases. Int J Mol Sci, 16:26087-26124.
[30] Hutchison, N Fligny, C., and Duffield, J. S. 2013. Resident Mesenchymal cells and Fibrosis. Biochim Biophys Acta, 1832(7): 962-971.
[31] Senoo H., Kojima N, Sato M, 2007. Vitamin A-storing cells (stellate cells). Vitam Horm, 75:131-159.
[32] Moreira, R.K., 2007. Hepatic Stellate Cells and liver Fibrosis. Arch Pathol Lab Med, 131: 1728-1734.
[33] Winau F, Hegasy G, Weiskirchen R, Weber S, Cassan C, Sieling PA, Kaufmann SH, 2007. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity, 26:117-129.
[34] Lingwal, P., Bhaat, G.K., and Kothiyal, P. 2015. Hepatic Stellate Cells as a Target for The treatment of liver fibrosis. Int J of Pharma Research and Review, 4(7):32-37.
[35] Karin, D., Koyama, Y., Brenner, D., and Kisseleva, T. 2016. The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis. Differentiation, 92: 84–92.
[36] Xia JL, Dai C, Michalopoulos GK, Liu Y, 2006. Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am J Pathol, 168:1500-15 12.
[37] Kalluri R, Neilson EG, 2003. Epithel-mesenchymal transition and its implication for fibrosis. J Clin Invest, 112:1776-1784.
[38] Zeisberg M and Kalluri R, 2004. The role of epithelial to mesenchymal transition in renal fibrosis. J Mol Med, 82:175-181.
[39] Wells, R.G. 2010. Epithelial to Mesenchymal Transition in liver fibrosis : Here Today, Gone Tomorrow. Hepatology, 51(3):737-740.
[40] Zeisberg, M., and Neilson, E.G. 2009. Biomarkers for Epithelial-mesenchymal transitions. The of Clin invest, 119(6):1429-1437.
[41] Quan TE, Cowper SE, Bucala R, 2006. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep, 8:145-150.
[42] Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB, 2005. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol, 166:675-684.
[43] Griffith, J.W., Sokol, C.L., and Luster, A.D. 2009. Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity. Annu Rev Immunol, 32:659-702.
[44] Russo FP, Alison MR. Bigger BW, Amofah E, Florou A, Amin F, Bou-Ghanios G, Jeffery R, Iredale JP, Forbes SJ, 2006. The bone marrow functionally contributes to liver fibrosis. Gastroenterology, 130:1807-1821.
[45] Zhao, Y.L., Zhu, R.T., and Sun, Y. L. 2016. Epithelial-mesenchymal transition in liver fibrosis (Review). Biomed Rep, 4: 269-274.
[46] Hinz B, 2007. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol, 127:526-537.
[47] Vladimir, K. 2014. Myofibroblast in Normal and Fibrotic Liver in Different Animal species. Acta Veterinaria-Beograd, 64(4):397-412.
[48] Iradale JP, 2007 Models of liver fibrosis
: exploring the dynamic nature of inflammation and repair in a solid organ. The Jour of Clin Invest, 117(3); 539-548.